Last reviewed 2026-04-20 · How we verify

Praemenstron (FLUMEDROXONE)

Phase 2 active Small molecule

Praemenstron (generic name: FLUMEDROXONE) is a flumedroxone drug. It is currently in Phase 2 development.

Praemenstron is thought to work by interacting with a specific biological target, although the exact nature of this interaction is not yet fully understood.

Praemenstron, also known as flumedroxone, is a small molecule drug of the flumedroxone class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential uses of praemenstron. It is not currently available as a generic medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FLUMEDROXONE
Drug class	flumedroxone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and the key to unlocking these locks is a specific shape that fits perfectly. Praemenstron is like a key that tries to fit into these locks, but we don't know which lock it's meant to open or how it will affect the body's overall function.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Praemenstron CI brief — competitive landscape report
Praemenstron updates RSS · CI watch RSS

Frequently asked questions about Praemenstron

What is Praemenstron?

Praemenstron (FLUMEDROXONE) is a flumedroxone drug.

How does Praemenstron work?

Praemenstron is thought to work by interacting with a specific biological target, although the exact nature of this interaction is not yet fully understood.

What is the generic name of Praemenstron?

FLUMEDROXONE is the generic (nonproprietary) name of Praemenstron.

What drug class is Praemenstron in?

Praemenstron belongs to the flumedroxone class. See all flumedroxone drugs at /class/flumedroxone.

What development phase is Praemenstron in?

Praemenstron is in Phase 2.

Drug class: All flumedroxone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing